Empagliflozin/linagliptin/metformin

Drug Profile

Empagliflozin/linagliptin/metformin

Alternative Names: Empagliflozin/linagliptin/metformin extended release; Empagliflozin/linagliptin/metformin XR

Latest Information Update: 12 Aug 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim; Eli Lilly
  • Class Antihyperglycaemics
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Diabetes mellitus

Most Recent Events

  • 15 Jul 2016 Chemical structure information added
  • 01 Jul 2016 Phase-I clinical trials in Diabetes mellitus (In volunteers) in Germany (PO) (NCT02821910)
  • 30 Jun 2016 Boehringer Ingelheim and Eli Lilly plan a phase I pharmacokinetics trial in Healthy volunteers in USA and Germany (NCT02821910)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top